Pacira BioSciences: Business Model, SWOT Analysis, and Competitors 2026

Pacira BioSciences, Inc. stands as a leading company in Healthcare. Generating $726.41 million in annual revenue (growing 5.1% year-over-year) and carrying a market capitalization of $983.47 million, the company has cemented its position as a foundational player in the global Drug Manufacturers - Specialty & Generic landscape. Under the leadership of its leadership team, Pacira BioSciences, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Pacira BioSciences, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Pacira BioSciences, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Pacira BioSciences, Inc.'s position in the Drug Manufacturers - Specialty & Generic market today.

What You Will Learn

1. How Pacira BioSciences, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Pacira BioSciences, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Pacira BioSciences, Inc.'s main competitors are and how the company compares on key financial metrics
4. Pacira BioSciences, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Pacira BioSciences, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $726.41 million annual revenue (TTM), +5.1% YoY
• Market Cap: $983.47 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 63.2%, operating margin -1.2%, net margin 1.0%
• Free Cash Flow: $108.56 million
• Return on Equity: 1.0% — reflects current investment phase
• Employees: 825 worldwide

Who Owns Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. is publicly traded on the NMS under the ticker symbol PCRX. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Pacira BioSciences, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Pacira BioSciences, Inc. has approximately 0.04 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $22.86 per share as of early 2026.

Pacira BioSciences, Inc.'s Mission Statement

Pacira BioSciences, Inc.'s strategic mission is aligned with its core business activities in the Drug Manufacturers - Specialty & Generic sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Pacira BioSciences, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Pacira BioSciences, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Pacira BioSciences, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Pacira BioSciences, Inc. Make Money?

As of 2026, Pacira BioSciences, Inc. generates $726.41 million in annual revenue (growing 5.1% year-over-year), with a 63.2% gross margin and -1.2% operating margin. Market capitalization stands at $983.47 million. Here is how the company generates its revenue:

Introduction

Pacira BioSciences is a pharmaceutical company that specializes in developing and commercializing innovative products for the acute care and ambulatory surgery markets. The company primarily generates revenue through the sale of its flagship product, EXPAREL®. This section will delve into how Pacira BioSciences makes money by leveraging its key revenue streams and business strategies.

EXPAREL® Sales

EXPAREL® is Pacira BioSciences' main source of revenue. It is an extended-release liposomal suspension that provides long-lasting pain relief after surgeries. EXPAREL® is designed to be administered directly to the surgical site, reducing the need for opioids and enhancing patient recovery.

The company generates revenue by selling EXPAREL® to hospitals, ambulatory surgery centers, and other healthcare providers. Pacira BioSciences has successfully established partnerships with various distribution channels, allowing for broad market access and product availability. EXPAREL® has gained significant market acceptance, contributing substantially to the company's revenue growth.

Growth Strategies

Pacira BioSciences employs several strategic initiatives to drive revenue growth and expand its market presence. These strategies include:

1. Market Expansion

The company focuses on expanding its market presence by increasing the adoption of EXPAREL® in new surgical procedures and patient populations. Pacira BioSciences invests in research and development to explore additional indications, formulations, and delivery methods for EXPAREL®. By expanding the applications of its flagship product, Pacira BioSciences aims to capture a larger market share and generate increased revenue.

2. Geographic Expansion

Pacira BioSciences is actively expanding its geographic reach by targeting new international markets. The company has successfully entered several European countries and continues to seek regulatory approvals for EXPAREL® in additional regions. By leveraging its global network and partnerships, Pacira BioSciences aims to tap into untapped markets, creating new revenue streams.

3. Strategic Collaborations

To further drive revenue growth, Pacira BioSciences seeks strategic collaborations with other pharmaceutical companies, healthcare providers, and research institutions. These collaborations aim to enhance the development, distribution, and commercialization of EXPAREL®. By leveraging the expertise and resources of its partne

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Pacira BioSciences, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Pacira BioSciences, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Pacira BioSciences, Inc. creates, delivers, and captures value.

Key Partners: Pacira BioSciences, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Drug Manufacturers - Specialty & Generic sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Pacira BioSciences, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Pacira BioSciences, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (825 employees), proprietary technology, and financial resources ($238.42M in cash).

Value Propositions: Pacira BioSciences, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Drug Manufacturers - Specialty & Generic market.

Customer Relationships: Pacira BioSciences, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Pacira BioSciences, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Pacira BioSciences, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Pacira BioSciences, Inc.'s major costs include cost of goods sold (36.8% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 101.2% of revenue.

Revenue Streams: Pacira BioSciences, Inc. generates revenue through its core product and service offerings.

Pacira BioSciences, Inc. Competitors

Pacira BioSciences, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Drug Manufacturers - Specialty & Generic segment of the Healthcare sector.

Pacira BioSciences, Inc. SWOT Analysis

A SWOT analysis examines Pacira BioSciences, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Pacira BioSciences, Inc.'s gross margin of 63.2% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -1.2% demonstrates disciplined cost management even at scale.

Weaknesses

• Leverage Risk: Pacira BioSciences, Inc.'s debt-to-equity ratio of 60.3 indicates meaningful financial leverage. Total debt stands at $418.20M against $238.42M in cash and equivalents.
• Thin Profit Margins: A net profit margin of 1.0% leaves limited buffer against revenue fluctuations or cost increases. Any significant market downturn could quickly pressure profitability.

Opportunities

• Total Addressable Market: Pacira BioSciences, Inc. operates in the Drug Manufacturers - Specialty & Generic segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Pacira BioSciences, Inc.'s products and services.
• Strategic Acquisitions: With $238.42M in cash and strong free cash flow generation, Pacira BioSciences, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pacira BioSciences, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pacira BioSciences, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Pacira BioSciences, Inc. enters 2026 as a leading company in Healthcare, backed by $726.41 million in annual revenue and a 1.0% net profit margin. The company's 63.2% gross margins and $108.56 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Pacira BioSciences, Inc.'s core markets.

For investors, Pacira BioSciences, Inc.'s 48.6x trailing P/E and 6.5x forward P/E reflect the market's expectations for stable earnings. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Pacira BioSciences, SEC EDGAR – Pacira BioSciences Filings, and Pacira BioSciences's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does Pacira BioSciences, Inc. do?

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgi

2. How much revenue does Pacira BioSciences, Inc. make?

Pacira BioSciences, Inc. generated $726.41 million in annual revenue (TTM), with 5.1% year-over-year growth.

3. What is Pacira BioSciences, Inc.'s market cap?

Pacira BioSciences, Inc.'s market capitalization is approximately $983.47 million as of early 2026.

4. Is Pacira BioSciences, Inc. profitable?

Yes. Pacira BioSciences, Inc. has a net profit margin of 1.0% and a return on equity of 1.0%.

5. Who are Pacira BioSciences, Inc.'s competitors?

Pacira BioSciences, Inc. competes in the Drug Manufacturers - Specialty & Generic sector against companies including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE).

6. Does Pacira BioSciences, Inc. pay dividends?

Pacira BioSciences, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is Pacira BioSciences, Inc.'s stock ticker?

Pacira BioSciences, Inc. trades on the NMS under the ticker symbol PCRX.

8. What is Pacira BioSciences, Inc.'s P/E ratio?

Pacira BioSciences, Inc.'s trailing P/E ratio is 48.6x and forward P/E is 6.5x, suggesting the market anticipates continued earnings growth.

9. How many employees does Pacira BioSciences, Inc. have?

Pacira BioSciences, Inc. employs approximately 825 people worldwide as of the most recent disclosure.

10. What is Pacira BioSciences, Inc.'s competitive advantage?

Pacira BioSciences, Inc.'s competitive advantages include its established brand, scale in Drug Manufacturers - Specialty & Generic, and track record of execution in the Healthcare sector.

Get your pitch deck scored by AI with investor-specific feedback, or use our AI Research Analyst for instant competitive analysis.